BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 17965195)

  • 1. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
    McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
    Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous cannabinoids and neutrophil chemotaxis.
    McHugh D; Ross RA
    Vitam Horm; 2009; 81():337-65. PubMed ID: 19647118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of cannabinoid receptor ligands: current status.
    Singh J; Budhiraja S
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
    Wilkinson JD; Williamson EM
    J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor.
    Steffens M; Zentner J; Honegger J; Feuerstein TJ
    Biochem Pharmacol; 2005 Jan; 69(1):169-78. PubMed ID: 15588725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
    Mo FM; Offertáler L; Kunos G
    Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoids and Their Pharmacological Actions.
    Pertwee RG
    Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery.
    Ho WS; Hiley CR
    J Pharm Pharmacol; 2004 Jul; 56(7):869-75. PubMed ID: 15233865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation.
    Patinkin D; Milman G; Breuer A; Fride E; Mechoulam R
    Eur J Pharmacol; 2008 Oct; 595(1-3):1-6. PubMed ID: 18778813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.
    Sterin-Borda L; Del Zar CF; Borda E
    Biochem Pharmacol; 2005 Jun; 69(12):1705-13. PubMed ID: 15885656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
    Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptors and their ligands.
    Pertwee RG; Ross RA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of cannabinoids.
    Grotenhermen F
    Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
    Bab I; Zimmer A; Melamed E
    Ann Med; 2009; 41(8):560-7. PubMed ID: 19634029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
    Svízenská I; Dubový P; Sulcová A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic neuroanatomy and neuropharmacology of cannabinoids.
    Breivogel CS; Sim-Selley LJ
    Int Rev Psychiatry; 2009 Apr; 21(2):113-21. PubMed ID: 19367505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
    Merighi S; Simioni C; Gessi S; Varani K; Borea PA
    Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.